Transthyretin familial amyloid polyneuropathy.
TTR FAP is characterized by phenotypic and genotypic heterogeneity. The severity of polyneuropathy along with autonomic dysfunction and heart involvement makes it a life-threatening disease. This protein is mainly produced by the liver. Molecular genetic testing is essential in the diagnostic strategy. TTR-Val30Met is the most frequent substitution, resulting in a guanine to cytosine mutation in exon 2 of the gene. It is virtually the only variant detected in Portugal, Brazil, and Sweden. By contrast, as many as 30 different TTR variants are reported in Japan and in other European countries. A less severe phenotype with late onset has been reported. Diagnosis should be performed as early as possible since upcoming pharmacological therapeutic approaches are now available, in addition to liver transplantation.
Department of Neurology, CHU Henri Mondor, Créteil, France; Inserm 1016, Université Paris-Descartes, Institut Cochin, Paris, France. Electronic address: violaine.plante@hmn.aphp.fr.
V
V
Planté-Bordeneuve
P
P
Kerschen
D000682:Amyloid / Q000378:metabolism; D028227:Amyloid Neuropathies, Familial / Q000150:complications / Q000235:genetics / Q000473:pathology / Q000628:therapy; D006801:Humans; D009154:Mutation / Q000235:genetics; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000235:genetics / Q000473:pathology / Q000628:therapy; D011228:Prealbumin / Q000235:genetics
D000682:Amyloid; D011228:Prealbumin
amyloidosis; genetics; neuropathy; therapeutics; transthyretin